ArticlePediatric cardiology2026
Decellularized Versus Standard Cryopreserved Homografts for Pulmonary Valve Replacement in the Ross Procedure.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The optimal right ventricular outflow tract (RVOT) conduit in the Ross procedure remains controversial. This study addresses outcomes of decellularized (DH) and cryopreserved homografts (CH) for RVOT reconstruction. Patients aged 8 years or older who underwent the Ross procedure using DH or CH were reviewed. Conduit durability and pulmonary valve function were compared between both groups. A total of 59 patients were included (26 DH-patients and 33 CH-patients). The median age at Ross procedure (DH: 19 (IQR: 13-30) vs. CH: 15 (IQR: 12-23) years, p = 0.150) and the homograft diameters (DH: 24 (22-26) vs. CH: 23 (22-24) mm, p = 0.163) were similar between the groups. When comparing postoperative events within the first 5 years between the groups, none of the DH-patients experienced infective endocarditis, homograft explantation, or catheter intervention. Whereas, in the CH group, 2 patients developed infective endocarditis, 2 underwent explantation, and one underwent Melody implantation. Following up with serial echocardiography for up to 5 years, none of the DH-patients developed significant pulmonary stenosis (PS > 40 mmHg), and one patient developed significant pulmonary regurgitation (PR: moderate or worse). In contrast, 2 patients in the CH group demonstrated significant PS, and 5 patients showed significant PR. Freedom from graft dysfunction, defined by endocarditis, explantation, Melody implantation, significant PS, and significant PR, tended to be better in DH than CH (90.9% vs. 79.0% at 5 years, p = 0.155). Our results demonstrated better short-term valve performance with DH than with CH following the RVOT reconstruction during the Ross procedure.
Indexed as
Identifiers
42184037What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.